



## **COVID-19 – Commercially Purchased Bebtelovimab Reimbursement**

Louisiana Department of Health posted [Informational Bulletin 22-28](#) on commercially purchased bebtelovimab reimbursement (Q0222).

For dates of service on or after August 15, 2022, claims will require modifier “UC” to identify that the COVID-19 medication administered was commercially purchased. Providers are to use the same administration codes for both the purchased product and the medication supplied by the federal government.

There are no changes for submitting claims related to the government-supplied medication. If the federal government provided the medication, then no modifier is to be appended and reimbursement is \$0. Seeking reimbursement for the government-provided medication is subject to review, recoupment and further sanctions.

UHC will reprocess any claims that were not paid in accordance with this update.

For more information:

- [Louisiana Department of Health Informational Bulletin 22-28: COVID-19 – Commercially Purchased Bebtelovimab Reimbursement.](#)
- [COVID-19 Prof\\_Out-Hosp\\_Vac.pdf \(lamedicaid.com\)](#)

### **Questions?**

For answers to specific coverage or claims questions, please call the Provider Call Center at 866-675-1607.